Lift weights on tirzepatide: resistance training preserved 1 kg of muscle in 40 weeks
GLP-1 drugs keep racking up wins — and complications.
This week's research shows they're reshaping treatment for everything from heart disease to osteoarthritis, while raising harder questions about muscle loss, genetic mismatch, and what happens when 1 in 5 users goes off-label.
🏋️ Lift While You Lose: Resistance Training Protects Muscle During Tirzepatide Therapy
- In a 40-week randomized trial of 120 adults with obesity, adding three weekly resistance exercise sessions to tirzepatide preserved about 1 kg more lean soft tissue mass compared to tirzepatide alone — without changing total weight loss (~22 kg in both groups).
- The exercise group also gained upper and lower body strength across the board. The tirzepatide-only group lost strength in every measure tested.
- Fat loss was nearly identical between groups, meaning resistance training carved out a cleaner body composition outcome without touching the scale.
Why it matters: Tirzepatide's weight loss is real, but so is the muscle loss that comes with it. This trial offers a concrete, low-cost adjunct — and reframes the conversation from "how much do you lose" to "what exactly are you losing."
Key Findings
🧬 Wrong Gene, Wrong Drug: Rare Variants Cut Semaglutide Response — But Not Tirzepatide's
- Among 13,725 GLP-1 drug users in a real-world genomic database, people carrying rare damaging variants in the GLP-1 receptor gene lost significantly less weight on semaglutide than matched non-carriers.
- Switch to tirzepatide — which hits a second receptor — and those same carriers achieved near-normal weight loss. Rare variants in the second receptor gene didn't blunt tirzepatide's effect either.
💊 1 in 10 U.S. Adults Took a GLP-1 Drug Last Year — and 2 in 5 Modified Their Dose
- CDC survey data from mid-2025 found roughly 10% of U.S. adults reported GLP-1 use in the past year. About 1 in 5 of those users took a compounded version not reviewed by the FDA for safety or quality.
- Around 40% of users modified how they took their medication — often citing cost or availability — with the highest rates of modification among younger adults.
🦴 Triple Agonist Cuts Knee Pain in People With Obesity in Phase 3 Trial
- Retatrutide — an investigational drug targeting three metabolic receptors simultaneously — was tested in adults with knee osteoarthritis and obesity, published in the New England Journal of Medicine.
- The trial found meaningful reductions in knee pain, extending the potential use of next-generation incretin drugs well beyond blood sugar and body weight.
🫀 Survodutide Passes Cardiovascular Safety Bar in High-Risk Obesity Trial
- The SYNCHRONIZE-CVOT phase 3 trial tested survodutide — a dual glucagon and GLP-1 receptor agonist — in adults with obesity and elevated cardiovascular risk, reporting results in The Lancet.
- The trial established cardiovascular safety for this newer drug class, a required regulatory hurdle that earlier-generation obesity drugs failed to clear.
💉 Blocking Two Muscle-Loss Signals During Semaglutide Therapy Preserved Lean Mass
- The COURAGE phase 2 trial tested antibodies blocking GDF8 (myostatin) and activin A — two proteins that suppress muscle growth — in people losing weight on semaglutide.
- The combination approach preserved lean mass during semaglutide-induced weight loss, published in The Lancet, pointing toward a potential pharmacological strategy for the muscle-loss problem.
🧠 GLP-1 Drug Didn't Add Benefit for Smoking Cessation on Top of Standard Care
- In a 71-person neuroimaging sub-trial, 12 weeks of dulaglutide added to varenicline and behavioral counseling produced no significant improvement in abstinence rates, craving, or brain activation compared to placebo.
- Abstinence was 54% with dulaglutide versus 68% with placebo — not a statistically significant difference, but a result that suggests a ceiling effect when first-line therapy is already strong.
Implications
GLP-1 drugs are expanding faster than the evidence can keep up — into joints, muscles, brains, and bariatric aftercare. The clearest unresolved tension: as genetic data shows these drugs work differently depending on who's taking them, the field still lacks prospective tools to match patients to the right drug before the first dose.
Studies in this issue
Primary sources used for this newsletter.
- Resistance exercise to reduce muscle loss during tirzepatide treatment for obesitymain storyNature medicine2026-11-09PMID 43003902
- Preventing muscle loss during weight loss with Trevogrumab alone or with Garetosmab in people with obesitykey findingLancet (London, England)2026-11-11PMID 43014326
- Weekly Retatrutide for Knee Osteoarthritis Pain in Adults with Obesitykey findingThe New England journal of medicine2026-11-09PMID 43001755
- Use and Changes in Glucagon-Like Peptide-1 Medicine Use Among Adults in the United States, 2025key findingMMWR. Morbidity and mortality weekly report2026-11-12PMID 43019237
- Heart health results with survodutide in adults with obesity and higher heart riskkey findingLancet (London, England)2026-11-09PMID 43003106
- Rare GLP1R gene changes reduce weight loss with semaglutide but not tirzepatidekey findingNature metabolism2026-11-11PMID 43015368
- Dulaglutide's effects on brain function and structure during quitting smokingkey findingBrain communications2026-11-11PMID 43011533
Continue reading
All GLP-1 Therapies issuesGet the next GLP-1 Therapies issue
Seven papers, once a week. Free.